NCT00192114 is a Phase 2 clinical trial of Enzastaurin HCl in Colonic Neoplasms, sponsored by Eli Lilly and Company.

Who is sponsoring NCT00192114?

NCT00192114 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT00192114?

Interventions in NCT00192114: Enzastaurin HCl.

What condition does NCT00192114 study?

NCT00192114 studies Colonic Neoplasms.

Is NCT00192114 still recruiting?

NCT00192114 is currently completed. Last updated 23 July 2020.

Are results published for NCT00192114?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-07-23 · How we verify

NCT00192114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study of Oral Enzastaurin HCl in Patients With Metastatic Colorectal Cancer

Completed Phase 2 Results posted Last updated 23 July 2020

What this trial tests

Phase 2 trial testing Enzastaurin HCl in Colonic Neoplasms in 28 participants. Completed in 1 March 2008.

Timeline

1 August 2005

Primary endpoint
1 March 2008

1 March 2008

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	1 August 2005
Primary completion	1 March 2008
Estimated completion	1 March 2008
Sites	3 locations across Denmark, Sweden

Drugs / interventions tested

Enzastaurin HCl — full drug profile →

Conditions studied

Colonic Neoplasms — all drugs for Colonic Neoplasms →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

19 and older, any sex, with Colonic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Participants With Progression Free Survival (PFS) at 6 Months
Time frame: Baseline to 6 months
PFS defined as time from date of first dose of enzastaurin to first date of documented progressive disease (PD) or date of death (any cause), whichever occurred first. Using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) PD defined as ≥20% increase in sum of the longest diameter (LD) of target lesions, taking as reference smallest sum LD recorded since treatment started or appearance o

Sponsor's own description

Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive review of targeted therapy for colorectal cancer.
Xie YH, Chen YX, Fang JY. · · 2020 · cited 1162× · PMID 32296018 · DOI 10.1038/s41392-020-0116-z
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD, Are C. · · 2024 · cited 105× · PMID 38542151 · DOI 10.3390/ijms25063178

Verify or expand the search:

Other recruiting trials for Colonic Neoplasms

Currently open trials in the same condition.

NCT07173985 — Strategies for Optimizing a Mailed FIT Program in Appalachia · NA · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06371898 — Comparison of MORbidity of Submucosal DIssection Resection of Giant cOlon Lesions Versus Surgery: a National Multicenter · active not recruiting
NCT06119867 — CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE) · Phase 3 · recruiting
NCT06124378 — Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer · Phase 2 · active not recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00192114 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 23 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00192114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing